Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861910 | 0.95 | RARB (0.68) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL9361418 | 0.95 | RARB (0.68) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL13448825 | 0.95 | RARB (0.68) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL15562010 | 0.95 | RARB (0.68) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL9019628 | 0.95 | RARB (0.68) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL2882011 | 0.91 | PLA2G4B (0.70) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL196110 | 0.90 | PKM (0.88) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL6132822 | 0.89 | TP53 (0.75) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL6132656 | 0.89 | TP53 (0.75) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL18682480 | 0.89 | TP53 (0.75) | PKMMAPK1TSHRTP53PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| CN-111936471-B | Non-fused thiophene derivatives and uses thereof | 埃尼奥制药公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118027412-A | Photo-alignment material | 罗利克技术有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-12-12 | — | — | US | disclosed |
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-09-26 | — | — | US | disclosed |
| CN-111386118-B | Combination pharmaceutical agents as RSV inhibitors | 英安塔制药有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-1670805-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20050072963-A1 | Liquid crystal compounds | QINETIQ LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| WO-2005028484-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1470105-A1 | LIQUID CRYSTAL COMPOUNDS | Qinetiq Limited (GB) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003064381-A1 | LIQUID CRYSTAL COMPOUNDS | QINETIQ LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-08-15 | — | — | US | disclosed |
| US-6355633-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-12 | — | — | US | disclosed |
| WO-2000058277-A1 | ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
| US-4009208-A | N,N'-HEPTAMETHYLENEBIS(4-METHOXYBENZAMIDE) | STERLING DRUG INC. (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | PKM 625/4885MAPK1 2860/4885TSHR 1396/4885 |
| US-20050072963-A1 | Liquid crystal compounds | C1S, SCO2, F12 | PKM 2607/4885MAPK1 2134/4885TSHR 2862/4885 |
| US-20050065151-A1 | Thiazolopyridine | ADORA2A, ADORA3, ADORA1 | PKM 1839/4885MAPK1 3067/4885TSHR 78/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | PKM 625/4885MAPK1 2860/4885TSHR 1396/4885 |
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | PKM 769/4885MAPK1 4572/4885TSHR 1240/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | PKM 625/4885MAPK1 2860/4885TSHR 1396/4885 |
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | FSHR, GNRHR, LHCGR | PKM 4553/4885MAPK1 1934/4885TSHR 29/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | PKM 3237/4885MAPK1 1820/4885TSHR 4229/4885 |
| US-11840527-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | PKM 769/4885MAPK1 4572/4885TSHR 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.